Retatrutide vs Ozempic (Semaglutide): A Research Comparison
Quick Answer
Ozempic contains semaglutide — a single GLP-1 receptor agonist (first-generation, one receptor). Retatrutide (LY3437943) is a triple agonist — it activates GLP-1, GIP and glucagon receptors simultaneously (third-generation, three receptors). They share the GLP-1 receptor as a common target, but retatrutide adds GIP receptor signalling (linked to fat tissue and insulin amplification in research models) and glucagon receptor signalling (linked to energy expenditure and hepatic glucose handling). For researchers, this means retatrutide offers access to three mechanistic pathways simultaneously — something a single GLP-1 agonist cannot provide.
Semaglutide (Ozempic / Wegovy)
Class: GLP-1 receptor agonist (single agonist)
Mechanism: Binds and activates the GLP-1 receptor only. In preclinical research models, GLP-1 receptor activation is linked to glucose-dependent insulin secretion from pancreatic beta cells, reduced glucagon secretion, slowed gastric emptying, and appetite-suppression signals in the hypothalamus.
Research generation: First-generation incretin receptor agonist. Established the GLP-1 receptor agonism framework that dual and triple agonists have since built upon.
Published research: Extensively characterised across Phase 1–3 trials and approved by the MHRA and FDA for specific indications. The published dataset underpins the mechanistic framework for GLP-1 receptor research.
Note: Semaglutide (Ozempic/Wegovy) is a licensed medicine. It is not supplied as a research peptide by Velox Peptides. This comparison exists to contextualise retatrutide's receptor profile relative to semaglutide, which researchers use as a reference compound when studying incretin receptor mechanisms.
Retatrutide (LY3437943)
Class: Triple GLP-1 / GIP / glucagon receptor agonist
Mechanism: A single peptide molecule engineered to bind and activate three G-protein-coupled receptors simultaneously. The GLP-1 receptor component mirrors semaglutide's primary mechanism. The GIP receptor component adds adipose tissue signalling and amplified insulin secretion (from research models). The glucagon receptor component adds hepatic glucose output and energy expenditure signalling — the pathway not present in semaglutide or tirzepatide.
Research generation: Third-generation incretin receptor agonist. The first triple-agonist compound to be studied in Phase 1/2 clinical trials.
Published research: Characterised in Cell Metabolism 2022 (preclinical), The Lancet 2022 (Phase 1b), and NEJM 2023 (Phase 2, 338 participants, 48 weeks). Phase 3 ongoing. Not yet approved.
Supply (Velox Peptides): Available as lyophilised powder, HPLC-verified ≥99% purity, 10mg and 20mg vials, UK 24h dispatch. View product page →
Side-by-Side Comparison
| Property | Semaglutide (Ozempic) | Retatrutide (LY3437943) |
|---|---|---|
| GLP-1 receptor agonism | ✓ Primary mechanism | ✓ One of three mechanisms |
| GIP receptor agonism | ✗ Not engaged | ✓ Second mechanism |
| Glucagon receptor agonism | ✗ Not engaged | ✓ Third mechanism |
| Total receptor targets | 1 | 3 |
| Research generation | First generation | Third generation (triple) |
| Developer | Novo Nordisk | Eli Lilly |
| Clinical status | Approved (MHRA / FDA) | Phase 3 (not approved) |
| Research peptide availability (UK) | Not available as research reagent | Available — Velox Peptides |
What the Extra Receptors Add
The core mechanistic question between retatrutide and semaglutide is: what do the additional GIP and glucagon receptor pathways contribute that GLP-1 agonism alone does not?
GIP receptor — what it adds over GLP-1 alone
GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors are expressed in pancreatic beta cells, adipose (fat) tissue, bone, and the brain. In preclinical research models, GIP receptor activation is linked to amplified insulin secretion beyond what GLP-1 agonism alone produces, and to signalling in adipose tissue related to lipid handling.
Finan et al. (2013) demonstrated in rodent, primate, and early human data that co-agonism of GLP-1 and GIP receptors in a single molecule produced greater metabolic research effects than either agonist alone — suggesting synergism rather than simple additivity.[3] Tirzepatide (Mounjaro) is the first approved dual GLP-1/GIP agonist. Retatrutide adds the glucagon receptor on top.
Glucagon receptor — what it adds over GLP-1 and GIP
Glucagon receptors are expressed primarily in hepatocytes (liver cells). In research models, glucagon receptor activation is linked to hepatic glucose output (glycogenolysis and gluconeogenesis) and to increased energy expenditure (thermogenesis). This is the receptor pathway semaglutide and tirzepatide both lack.
Researchers investigating the energy expenditure axis of metabolic signalling — looking specifically at whether hepatic and thermogenic mechanisms contribute additively to multi-receptor agonism — use retatrutide to access this pathway in a single-compound experimental framework. Without a glucagon receptor agonist component, this axis is inaccessible from either semaglutide or tirzepatide.
Coskun et al. (2022) confirmed glucagon receptor activity in LY3437943 binding assays and observed in DIO mouse models that it contributed additional effects beyond those seen with a matched GLP-1/GIP dual compound — noting the glucagon receptor component's energy expenditure contribution as a key differentiator.[1]
Research Context: Which Compound for Which Question?
| Research question | More suitable compound |
|---|---|
| Isolate GLP-1 receptor effects only | Semaglutide (selective GLP-1 agonist) |
| Study combined GLP-1 + GIP receptor signalling | Tirzepatide (dual GLP-1/GIP agonist) |
| Study all three incretin/metabolic receptor pathways simultaneously | Retatrutide (triple GLP-1/GIP/glucagon agonist) |
| Investigate glucagon receptor contribution to multi-receptor metabolic signalling | Retatrutide (the only published triple agonist in this class) |
| Research requiring an approved compound with the widest published dataset | Semaglutide (approved, largest published dataset) |
Retatrutide's primary research advantage over semaglutide is access to three distinct mechanistic axes in a single compound. For researchers studying multi-receptor interactions in metabolic signalling, this removes the need to use multiple separate compounds and eliminates combinatorial confounders from dual-compound experiments.
Velox Peptides — Retatrutide for Research
Supplied as a research reagent only. Not a medicine. Not evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. PMID: 24174327
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 30120083
Frequently Asked Questions
What is the difference between retatrutide and Ozempic?
Ozempic (semaglutide) is a single GLP-1 receptor agonist — one receptor pathway. Retatrutide (LY3437943) is a triple agonist — it simultaneously activates GLP-1, GIP and glucagon receptors. The addition of GIP and glucagon receptor agonism introduces adipose tissue signalling, amplified insulin secretion, and hepatic energy expenditure pathways not present in semaglutide. All research observations — not therapeutic comparisons.
Is retatrutide the same as Ozempic?
No. They are different compounds from different manufacturers. Ozempic contains semaglutide (Novo Nordisk), a GLP-1 receptor agonist approved for specific indications. Retatrutide (LY3437943, Eli Lilly) is a triple agonist in Phase 3 development, not yet approved for any indication. They share GLP-1 receptor agonism as a common mechanism but differ substantially in their additional receptor profiles.
Is retatrutide stronger than semaglutide?
This cannot be answered in the context of therapeutic claims. From a research mechanism perspective, retatrutide engages three receptor pathways vs semaglutide's one, providing researchers with access to GIP and glucagon receptor signalling not available from semaglutide alone. Whether that translates to different outcomes in any specific experimental model depends on the experimental design and model system.
Can I buy retatrutide in the UK for research?
Yes. Velox Peptides supplies retatrutide (LY3437943) as a research reagent in the UK. HPLC-verified at ≥99% purity, 10mg and 20mg vials, dispatched from Northern Ireland within 24 hours. View the product page →
Is retatrutide approved?
No. As of June 2026, retatrutide has not been approved by the MHRA or FDA for any indication. It is in Phase 3 clinical trials (the TRIUMPH programme by Eli Lilly). It is legal to purchase in the UK for in vitro research use only.
